Company profile: Centessa Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies and platforms, including SerpinPC, a biologic for hemophilia that inhibits activated protein C to reduce bleeding; an Orexin Receptor 2 agonist program for sleep-wake disorders; the LockBody technology platform designed to enhance immuno-oncology by selectively targeting the tumor microenvironment; and LB101, a conditionally tetravalent PD-L1 X CD47 bispecific monoclonal antibody for advanced solid tumors.
Products and services
- LockBody Technology Platform: architects a tumor-microenvironment-selective platform designed to enhance immuno-oncology treatment by selectively targeting the tumor microenvironment for oncology applications
- LB101: engineers a conditionally tetravalent PD-L1 × CD47 bispecific monoclonal antibody for treating advanced solid tumors, enabling simultaneous PD-L1 and CD47 target engagement
- SerpinPC: produces an APC-targeted biologic for hemophilia that inhibits activated protein C to reduce bleeding
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Centessa Pharmaceuticals
AbbVie
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbbVie company profile →
Lanthiopharma
HQ: The Netherlands
Website
- Description: Provider of drug discovery focused on therapeutic lantipeptide drugs for serious diseases, applying proprietary lanthionine-peptide technology (LanthioPepTM) to generate novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lanthiopharma company profile →
LEAF Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAF Pharmaceuticals company profile →
Annovation BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical products focused on anesthesia, sedation and sleep; incorporated in 2009 and based in Wayland, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annovation BioPharma company profile →
NPS Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapies for rare diseases, dedicated to making a difference in the lives of patients who often have few, if any, treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NPS Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Centessa Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Centessa Pharmaceuticals
2.2 - Growth funds investing in similar companies to Centessa Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Centessa Pharmaceuticals
4.2 - Public trading comparable groups for Centessa Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →